SCHEMBL4496674

SCHEMBL4496674

OCc1ccc2[nH]c(NCC3CCN(Cc4cccc5ccccc45)CC3)nc2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 2/20 0.43
OPRM1 P35372 3/20 0.42
OPRK1 P41145 3/20 0.42
OPRL1 P41146 2/20 0.42
SIGMAR1 Q99720 2/20 0.41
PIK3CB P42338 1/20 0.41
HDAC1 Q13547 1/20 0.40
HDAC8 Q9BY41 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
HTR2A P28223 1/20 0.39
HTR2C P28335 1/20 0.39
HTR2B P41595 1/20 0.39
GRIN1 Q05586 2/20 0.39
GRIN2B Q13224 2/20 0.39
TSHR P16473 1/20 0.39
KDM4E B2RXH2 1/20 0.38
MEN1 O00255 1/20 0.38
NPC1 O15118 1/20 0.38
MAPT P10636 1/20 0.38
BLM P54132 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4497481 0.86 SMN1; SMN2 (0.44) ACHEOPRM1OPRK1OPRL1SIGMAR1
SCHEMBL4494897 0.85 ACHE (0.43) ACHEOPRM1OPRK1OPRL1SIGMAR1
SCHEMBL4509816 0.85 OPRM1 (0.43) ACHEOPRM1OPRK1OPRL1SIGMAR1
SCHEMBL4507510 0.84 OPRM1 (0.43) ACHEOPRM1OPRK1OPRL1SIGMAR1
SCHEMBL4509574 0.84 HSD17B10 (0.44) ACHEOPRM1OPRK1OPRL1SIGMAR1
SCHEMBL4505044 0.84 ACHE (0.42) ACHEOPRM1OPRK1OPRL1SIGMAR1
SCHEMBL4502250 0.79 ACHE (0.48) ACHEOPRM1OPRK1OPRL1SIGMAR1
SCHEMBL4493806 0.74 ACHE (0.43) ACHEOPRM1OPRK1OPRL1SIGMAR1
SCHEMBL4491399 0.71 OPRM1 (0.49) ACHEOPRM1SIGMAR1HTR2BGRIN1
SCHEMBL4496677 0.71 SLC6A4 (0.34) PIK3CBMEN1MAPTKMT2ASLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7517875-B2 Piperidine derivatives having CCR3 antagonism TEIJIN LIMITED (JP) 2009-04-14 US disclosed
US-20070032525-A1 Piperidine derivatives having ccr3 antagonism TEIJIN LIMITED, A JAPANESE BODY CORPORATE (JP) 2007-02-08 US disclosed
EP-1502916-A1 PIPERIDINE DERIVATIVES HAVING CCR3 ANTAGONISM TEIJIN LIMITED (JP) 2005-02-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032525-A1 Piperidine derivatives having ccr3 antagonism CCR3, CCR1, CCR4 ACHE 4551/4885OPRM1 388/4885OPRK1 306/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.